GSK_219606 AZUR-2: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in P

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

GSK_219606 AZUR-2: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Objective

Clinical Trial Details

Contact

Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org

Avera Cancer Institute — Yankton
1115 W 9th St
Yankton, SD 57078
Main: 605-668-8850